| Summary: | 碩士 === 國立臺灣師範大學 === 高階經理人企業管理碩士在職專班(EMBA) === 103 === Using “Biotech and New Pharmaceutical Development Act "to provide tax incentives to technology, personnel and funding to encourage manufacturers to invest biotech drug development. As at the end of April 2014, there have been 70 new biotechnology company have been determined, biotechnology over 163 items of new drugs. As new drugs are expected to biotech products approved for sale abroad, will help to improve our global market share of the biotechnology industry.
This study with the Executive Yuan to promote "Taiwan biotech industry took off action plan", in addition to strengthening the industry value chain, the role of industrial development to complement the development of the biotechnology industry gap on the current; at the same time in response to domestic and international biotechnology industry trends, in order to development of specialty products, birth flagship company, expand investment three strategies; and with the government backbone enterprise, industry professionals rooted promoting measures such as the cross-strait bridge project, and the use of various investment incentives to accelerate the development of the biotechnology industry.
In response to the competitive trends, expectations set by this study and further development strategy of Center Laboratories, Inc. In addition, by viewing the development of the biotechnology industry at domestic and international and to provide a reference and to learn from the company, hoping to form a specific reference to provide relevant decision-making body of the company and the industry, such as the time to develop strategies. This study will become a student of the internationally renowned high-quality specialty products and technical skills of medical professional manufacturers.
Keywords:Taiwan biotech industry, Growth strategy analysis, Center pharmaceutical.
|
|---|
